# A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.

> **NCT07199257** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 144 (estimated)

## Conditions studied

- Allergic Rhinitis, Seasonal

## Interventions

- **BIOLOGICAL:** GR1802 injection
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07199257
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-25
- **Primary completion:** 2027-05-15
- **Final completion:** 2027-07-31
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07199257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07199257, "A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07199257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*